FDA advisory vote on TLANDO not a knockout for Lipocine

   FDA advisory vote on TLANDO not a knockout for Lipocine

Although Lipocine (NASDAQ:LPCN) is disappointed by a FDA advisory committee vote against the benefit/risk profile of TLANDO, its oral testosterone replacement therapy (TRT), the company believes there is still a path forward for TLANDO.

Read More

Clearside Biomedical to report key milestones in 2018

Clearside Biomedical to report key milestones in 2018

Clearside Biomedical (NASDAQ:CLSD) is expected to report several key milestones in 2018 in its programs of developing potential treatments for back of the eye diseases with its corticosteroid therapy, CLS-TA, administered through the suprachoroidal space (SCS) to readily access the retina and choroid and thereby target disease pathology. 

Read More

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

Closely-held Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have failed first line treatment, as well as patients with advanced pancreatic and ovarian cancers.

Read More

Crescita targeting $50-million in revenue in 5 years

Crescita targeting $50-million in revenue in 5 years

Crescita Therapeutics (TSX:CTX), is aiming to be a $50-million commercial dermatology company in the next five years, with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, their diseases and their symptoms.

Read More

BioLight dry eye subsidiary approaching CE Mark filing, U.S. pivotal trial

BioLight dry eye subsidiary approaching CE Mark filing, U.S. pivotal trial

DiagnosTear, the dry eye diagnostic subsidiary of BioLight Life Sciences (TASE:BOLT), hopes to file by the end of 2017 for CE Mark approval in Europe and begin a pivotal trial in the U.S. in mid-2018 with its TeaRx device to aid in the diagnosis and monitoring of dry eye syndrome (DES).

Read More

Mazor’s odyssey to spine robotic surgery leader

Mazor’s odyssey to spine robotic surgery leader

Since its founding 15 years ago, Mazor Robotics (NASDAQ, TASE:MZOR) has overcome challenges typical to medical device startups to become the leader and possibly the standard of care in spine robotics surgery.

Read More

Flex Pharma focused on 3 clinical readouts in 2018

Flex Pharma focused on 3 clinical readouts in 2018

Flex Pharma (NASDAQ:FLKS) expects to report clinical readouts in 2018 from three Phase 2 studies of its anti-cramping drug candidate, FLX-787, in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS).

Read More

In conversation with Hrishikesh Suresh of NeuroGate

In conversation with Hrishikesh Suresh of NeuroGate

As CEO and one of three co-founders of upstart NeuroGate, Hrishikesh Suresh currently is completing his final year as a medical student at McMaster University in Hamilton, Ontario and plans to pursue a six-year residency in neurosurgery. But since the age of 12, he has had a passion for computer coding and, as a result, contributed to the company’s software development, which aims to capture motion data as a method to diagnose neurodegenerative diseases...

Read More

BiondVax to start pivotal universal flu vaccine trial next year

BiondVax to start pivotal universal flu vaccine trial next year

BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) expects to be Phase 3 ready in 2018 to begin pivotal testing in Europe of a universal flu vaccine with the potential to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.

Read More

Profound makes leap to platform company from prostate product

Profound makes leap to platform company from prostate product

With its recent acquisition of Royal Philips’ (NYSE:PHG; AEX:PHIA) Sonalleve business, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is making the leap from a medical device company focused on prostate cancer ablation to a platform company, offering real-time magnetic resonance (MR)-guidance as the imaging platform and ultrasound as the energy source for the delivery of non-invasive ablative technology to clinicians.

Read More

In conversation with Lloyd Segal of Repare

In conversation with Lloyd Segal of Repare

As president and CEO of upstart Repare Therapeutics, Lloyd Segal was instrumental is arranging the initial funding to create Repare while he served as an entrepreneur-in-residence at Versant Ventures, a leading healthcare investment firm with a hands-on approach to company building. Repare is developing precision oncology drugs that target specific vulnerabilities of tumor cells...

Read More